文献速递临床微生物质量管理与危急值

头孢地尔药敏试验:纸片扩散法与肉汤微量稀释法的比较

Cefiderocol Antimicrobial Susceptibility Testing against Multidrug-Resistant Gram-Negative Bacilli: a Comparison of Disk Diffusion to Broth Microdilution.
PubMed 文献 · J Clin Microbiol · 2020-12-17

该研究比较了头孢地尔纸片扩散法(DD)与肉汤微量稀释法(BMD)对多重耐药革兰阴性杆菌的药敏试验性能。对58株碳青霉烯耐药肠杆菌目和50株非发酵革兰阴性杆菌进行检测,结果显示DD与BMD的类别一致性为75%至90%,但DD对鲍曼不动杆菌复合体表现不佳,且不同解释标准(CLSI、FDA、EUCAST)间存在显著差异。

要点

  • 头孢地尔纸片扩散法与肉汤微量稀释法的类别一致性范围为75%至90%。
  • 纸片扩散法对鲍曼不动杆菌复合体的检测性能较差。
  • CLSI、FDA和EUCAST三种解释标准间的敏感性结果存在显著差异。

核心结论

  • 纸片扩散法可作为头孢地尔药敏试验的便捷替代方法,但鲍曼不动杆菌复合体除外。
  • 使用CLSI、FDA和EUCAST折点解释头孢地尔药敏结果时存在相当大的变异性。

研究设计与样本

  • 研究纳入连续收集的碳青霉烯耐药肠杆菌目58株和非葡萄糖发酵革兰阴性杆菌50株。
  • 采用肉汤微量稀释法(冻干板;Sensititre;Thermo Fisher)和纸片扩散法(30 μg;研究用MASTDISCS和FDA批准的HardyDisks)进行头孢地尔药敏试验。
  • 使用FDA(2020年9月28日更新前)、EUCAST和研究性CLSI折点解释结果,计算类别一致性、小错误、大错误和极重大错误。

主要发现

  • 所有分离株经BMD检测的敏感性分别为72%(FDA)、75%(EUCAST)和90%(CLSI)。
  • 纸片扩散法使用EUCAST折点时敏感性较低,HardyDisks为65%、MASTDISCS为66%;使用FDA折点分别为74%和72%;使用CLSI折点分别为87%和89%。
  • 类别一致性范围为75%至90%,小错误为8%至25%,大错误为0%至19%,极重大错误为0%至20%,并随纸片、革兰阴性杆菌类型和评估折点而变化。
  • 两种纸片扩散法对鲍曼不动杆菌复合体均表现不佳。

关键数值与推荐

  • 碳青霉烯耐药肠杆菌目58株,非葡萄糖发酵革兰阴性杆菌50株。
  • 纸片扩散法使用30 μg纸片(研究用MASTDISCS和FDA批准的HardyDisks)。
  • BMD敏感性:FDA 72%,EUCAST 75%,CLSI 90%。
  • DD敏感性范围:HardyDisks 65%至87%,MASTDISCS 66%至89%(取决于折点)。
  • 类别一致性75%至90%,小错误8%至25%,大错误0%至19%,极重大错误0%至20%。

临床怎么用

  • 纸片扩散法可用于头孢地尔药敏试验,但不应单独用于鲍曼不动杆菌复合体。
  • 解释头孢地尔药敏结果时需注意所采用折点(CLSI、FDA或EUCAST)带来的差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antimicrobial susceptibility testing (AST) of cefiderocol poses challenges because of its unique mechanism of action (i.e., requiring an iron-depleted state) and due to differences in interpretative criteria established by the Clinical and Laboratory Standards Institute (CLSI), U.S. Food and Drug Administration (FDA), and European Committee on Antimicrobial Susceptibility Testing (EUCAST). Our objective was to compare cefiderocol disk diffusion methods (DD) to broth microdilution (BMD) for AST of Gram-negative bacilli (GNB). Cefiderocol AST was performed on consecutive carbapenem-resistant Enterobacterales (CRE; 58 isolates) and non-glucose-fermenting GNB (50 isolates) by BMD (lyophilized panels; Sensititre; Thermo Fisher) and DD (30 μg; research-use-only [RUO] MASTDISCS and FDA-cleared HardyDisks). Results were interpreted using FDA (prior to 28 September 2020 update), EUCAST, and investigational CLSI breakpoints (BPs). Categorical agreement (CA), minor errors (mE), major errors (ME), and very major errors (VME) were calculated for DD methods. The susceptibilities of all isolates by BMD were 72% (FDA), 75% (EUCAST) and 90% (CLSI). For DD methods, EUCAST BPs demonstrated lower susceptibility at 65% and 66%, compared to 74% and 72% (FDA) and 87% and 89% (CLSI) by HardyDisks and MASTDISCS, respectively. CA ranged from 75% to 90%, with 8 to 25% mE, 0 to 19% ME, and 0 to 20% VME and varied based on disk, GNB, and BPs evaluated. Both DD methods performed poorly for Acinetobacter baumannii complex. There is considerable variability when cefiderocol ASTs are interpreted using CLSI, FDA, and EUCAST breakpoints. DD offers a convenient alternative approach to BMD methods for cefiderocol AST, with the exception of A. baumannii complex isolates.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Morris CP, Bergman Y, Tekle T, et al. Cefiderocol Antimicrobial Susceptibility Testing against Multidrug-Resistant Gram-Negative Bacilli: a Comparison of Disk Diffusion to Broth Microdilution. J Clin Microbiol. 2020. PMID: 32938734. doi:10.1128/JCM.01649-20

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。